Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBP-A19 in advanced solid tumors
NCT06990464Phase 1Recruiting
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Jun 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SIBP-A19 in solid tumor (advanced stage) and metastatic solid tumors, sponsored by Shanghai Institute of Biological Products. Primary endpoints: Adverse Events, Phase II Recommended Dose and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
SIBP-A19
03
Conditions
solid tumor (advanced stage)metastatic solid tumors
Beyond the preview
Go deeper on NCT06990464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06990464.